×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NVCT – nuvectis pharma, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NVCT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/17
07:16 am
nvct
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC [Yahoo! Finance]
Low
Report
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC [Yahoo! Finance]
12/17
07:00 am
nvct
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
Low
Report
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
12/3
08:44 am
nvct
Nuvectis Pharma (NASDAQ:NVCT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Nuvectis Pharma (NASDAQ:NVCT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/25
09:08 am
nvct
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC [Yahoo! Finance]
Low
Report
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC [Yahoo! Finance]
11/25
08:00 am
nvct
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
Medium
Report
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
11/8
07:05 pm
nvct
Director of Nuvectis Pharma Juan Sanchez Buys 20% More Shares [Yahoo! Finance]
Medium
Report
Director of Nuvectis Pharma Juan Sanchez Buys 20% More Shares [Yahoo! Finance]
11/4
08:15 am
nvct
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
Medium
Report
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
11/4
07:30 am
nvct
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
Medium
Report
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/6
08:01 am
nvct
Form 4 Nuvectis Pharma, Inc. For: Nov 05 Filed by: BENTSUR RON
Medium
Report
Form 4 Nuvectis Pharma, Inc. For: Nov 05 Filed by: BENTSUR RON
11/6
08:00 am
nvct
Form 4 Nuvectis Pharma, Inc. For: Nov 05 Filed by: Kaplan Matthew L.
Medium
Report
Form 4 Nuvectis Pharma, Inc. For: Nov 05 Filed by: Kaplan Matthew L.
11/6
08:00 am
nvct
Form 4 Nuvectis Pharma, Inc. For: Nov 05 Filed by: Sanchez Juan
Medium
Report
Form 4 Nuvectis Pharma, Inc. For: Nov 05 Filed by: Sanchez Juan
11/4
08:17 am
nvct
Form 8-K Nuvectis Pharma, Inc. For: Nov 04
Medium
Report
Form 8-K Nuvectis Pharma, Inc. For: Nov 04
11/4
08:02 am
nvct
Form 10-Q Nuvectis Pharma, Inc. For: Sep 30
Medium
Report
Form 10-Q Nuvectis Pharma, Inc. For: Sep 30
10/31
08:02 am
nvct
Form 4 Nuvectis Pharma, Inc. For: Sep 22 Filed by: Sanchez Juan
Low
Report
Form 4 Nuvectis Pharma, Inc. For: Sep 22 Filed by: Sanchez Juan
10/31
08:00 am
nvct
Form 3 Nuvectis Pharma, Inc. For: Sep 22 Filed by: Sanchez Juan
Low
Report
Form 3 Nuvectis Pharma, Inc. For: Sep 22 Filed by: Sanchez Juan
10/29
08:00 am
nvct
Form 4 Nuvectis Pharma, Inc. For: Oct 23 Filed by: Mosseri Marlio Charles
Low
Report
Form 4 Nuvectis Pharma, Inc. For: Oct 23 Filed by: Mosseri Marlio Charles
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: